Information  X 
Enter a valid email address

Omega Diagnostics Gp (ODX)

  Print   

Monday 31 January, 2022

Omega Diagnostics Gp

Speculation regarding a potential fundraise

RNS Number : 0627A
Omega Diagnostics Group PLC
31 January 2022
 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

Speculation regarding a potential fundraise

 

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products , notes the recent online speculation and confirms that it is in discussions with certain investors and shareholders regarding a potential equity fundraising.

 

Market conditions remain challenging and accordingly any issue of equity would be at a discount to the current share price.  Any fundraise would include an open offer to accommodate retail investors.

 

As per the announcement of 19 January, the Company has significant cash resources . Accordingly, there is no immediate need to raise additional capital and the Company may choose not to proceed with a fundraising until such time as conditions are more favourable.

 

A further announcement will be made in due course as necessary.

 

 

Contacts: 

 

Omega Diagnostics Group PLC 

www.omegadx.com

Jag Grewal, Chief Executive Officer 

via Walbrook PR

Chris Lea, Chief Financial Officer

 

 

 

finnCap Ltd  

Tel: 020 7220 0500

Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)

 

Alice Lane/ Charlotte Sutcliffe (ECM)

 

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Applegarth

Mob: 07584 391 303

Sam Allen

Mob: 07502 558 258

     

 

 

About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 75 countries and specialise in the areas of health and nutrition and global health.

www.omegadx.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSDEESSEESEDF

a d v e r t i s e m e n t